From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
Phase | Treatment | No. of OC patients | Selected toxicities | Efficacy | Reference |
---|---|---|---|---|---|
I | Perifosine (MTD = 150 mg/day) + docetaxel | 21 | Nausea, vomiting, anorexia, and fatigue | At MTD in 11 patients, PR in 1 PTEN-null patient, SD in 3 patients | Fu et al.[37] |
I | GSK795 (25, 50, or 75 mg/day) | 12 | Grade 2 anorexia (18%) and vomiting (18%) | 2 (16%) cases of SD for 6 months with tumor shrinkage of 26% and 11%, respectively | Gungor et al.[38] |
I | GSK211 (50–150 mg/day) + carboplatin (AUC = 5) + paclitaxel (175 mg/m2) | 29 | Grade 1/2 diarrhea, nausea, and fatigue | All patients in dose escalation: ORR = 30%; At MTD: ORR = 50% | Blagden et al.[39] |
At MTD: ORR = 50% |